5,5,8,8-四甲基-5,6,7,8-四氢-2-萘羰酰氯 | 104224-50-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 5,5,8,8-四甲基-5,6,7,8-四氢-2-萘羰酰氯
• 英文名称: 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphtholyl chloride
• 英文别名: 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthoyl chloride；5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene-2-carbonyl chloride；5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-carbonyl chloride；5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl chloride
• CAS: 104224-50-2
• 化学式: C₁₅H₁₉ClO
• 分子量: 250.768
• InChiKey: CPWIUCQCJRWWTH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R34
• 海关编码：
  2916399090

SDS

Name:	5 5 8 8-Tetramethyl-5 6 7 8-tetrahydro-2-naphthalenecarbonyl Material Safety Data Sheet
Synonym:	None Known
CAS:	104224-50-2

Section 1 - Chemical Product MSDS Name:5 5 8 8-Tetramethyl-5 6 7 8-tetrahydro-2-naphthalenecarbonyl Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
104224-50-2	5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro	97+	unlisted

Hazard Symbols: C
Risk Phrases: 14 29 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Reacts violently with water. Contact with water liberates toxic gas.
Causes burns.Water-reactive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Chronic exposure may cause effects similar to those of acute exposure.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid immediately.
Skin:
In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical aid immediately. Wash clothing before reuse.
Ingestion:
If swallowed, do NOT induce vomiting. Get medical aid immediately.
If victim is fully conscious, give a cupful of water. Never give anything by mouth to an unconscious person.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Water Reactive. Material will react with water and may release a flammable and/or toxic gas.
Extinguishing Media:
DO NOT USE WATER! Contact professional fire-fighters immediately.
Use dry chemical, dry sand, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation. Do not expose spill to water.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Keep container tightly closed. Do not ingest or inhale. Do not allow contact with water. Discard contaminated shoes.
Use only with adequate ventilation.
Storage:
Keep container closed when not in use. Keep away from water. Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 104224-50-2: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Oil
Color: pale yellow
Odor: slight
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 105-110 deg C @ 0.5mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C15H19OCl
Molecular Weight: 250.77

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Combines vigorously or explosively with water. Reacts with water to form hydrogen chloride, a toxic and corrosive gas.
Conditions to Avoid:
Contact with water.
Incompatibilities with Other Materials:
Bases, oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 104224-50-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenecarbonyl chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: Pseudomonas putida:

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE LIQUID, WATER-REACTIVE, N.O.S
Hazard Class: 8
UN Number: 3094
Packing Group: II
IMO
Shipping Name: CORROSIVE LIQUID, WATER-REACTIVE, N.O.S
Hazard Class: 8
UN Number: 3094
Packing Group: II
RID/ADR
Shipping Name: CORROSIVE LIQUID, WATER-REACTIVE, N.O.S
Hazard Class: 8
UN Number: 3094
Packing group: II

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 14 Reacts violently with water.
R 29 Contact with water liberates toxic gas.
R 34 Causes burns.
Safety Phrases:
S 6 Keep under nitrogen.
S 23 Do not inhale gas/fumes/vapour/spray.
S 24/25 Avoid contact with skin and eyes.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 104224-50-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 104224-50-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 104224-50-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5,5,8,8-四甲基-5,6,7,8-四氢-2-萘羰酰氯 在 Alkaline 作用下， 生成 4-[(5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基)甲酰氨基]苯甲酸
  参考文献：
  名称：

  Differentiation inducers of human promyelocytic leukemia cells HL-60. Phenylcarbamoylbenzoic acids and polyene amides.

  摘要：

  发现了新型的人类早幼粒细胞白血病(HL-60)细胞向成熟粒细胞分化的诱导剂，即4-(3,4-二异丙基苯基氨基甲酰)苯甲酸(2c)和4-(5,6,7,8-四氢-5,5,8,8-四甲基萘-2-氨基甲酰)苯甲酸(2d)。两种聚烯酰胺，作为维甲酸与酰胺化合物1a和2d的结构杂化体，也展现出生物活性，这一结果表明维甲酸与活性芳香酰胺之间存在着结构联系。

  DOI：

  10.1248/cpb.34.2275
• 作为产物：
  描述：

  2,5-二甲基-2,5-己二醇 在 盐酸 、 aluminum (III) chloride 、 potassium permanganate 、 氯化亚砜 、 N,N-二甲基甲酰胺 、 sodium hydroxide 作用下， 以 水 、 氯苯 为溶剂， 反应 33.0h， 生成 5,5,8,8-四甲基-5,6,7,8-四氢-2-萘羰酰氯
  参考文献：
  名称：

  一种维甲酸类衍生物Am580的合成方法

  摘要：

  本发明公开了一种维甲酸类衍生物Am580的合成方法，该方法包括以下步骤：将2,5‑二甲基己烷‑2,5‑二醇在浓HCl中的溶液搅拌30min，后向体系里通入HCl气体反应3h，后搅拌至体系变成两相混合物，冷却至室温，过滤得浅粉红色固体，用水洗涤，在甲醇中重结晶后过滤得到中间体3，产物为白色固体，将2,5‑二氯‑2,5‑二甲基己烷溶解在有机溶剂中，将AlCl3加入到溶液中，所述2,5‑二氯‑2,5‑二甲基己烷与AlCl3的摩尔比为1:0.1‑1:0.2，加热至100‑120℃搅拌16h后用3M HCl淬灭反应，并用正己烷萃取，减压蒸馏除去溶剂得到产物为无色油状物中间体4。本发明的有益效果是：本发明每步收率较高，后处理简单，更加易于工业化生产；本发明针对傅克反应以及氧化反应优化反应条件以及溶剂体系，更有利于工业化生产。

  公开号：

  CN112479918B

文献信息

• Di(aromatic) compounds and their use in human and veterinary medicine
  申请人：Centre International de Recherches Dermatologiques Galderma (Cird

  公开号：US05387594A1

  公开（公告）日：1995-02-07

  Di(aromatic) compounds corresponding to the following formula: ##STR1## in which: Ar represents either ##STR2## n=1 or 2 or: ##STR3## X represents a divalent radical, Z represents O, S or a divalent radical, and R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 represent a hydrogen atom or various organic radicals, and the salts of the compounds of formula (I) when R.sub.1 is a carboxylic acid function. Use in human and veterinary medicine and in cosmetics.

  对应以下公式的二芳基化合物：##STR1## 其中：Ar代表##STR2## n=1或2或：##STR3## X代表二价基团，Z代表O、S或二价基团，R.sub.1、R.sub.2、R.sub.3、R.sub.4和R.sub.5代表氢原子或各种有机基团，以及当R.sub.1是羧酸功能时，公式（I）化合物的盐。用于人类和兽医学以及化妆品。
• Antitumor Activity of 5-Aryl-2,3-dihydroimidazo[2,1-a]isoquinolines
  作者：William J. Houlihan、Paul G. Munder、Dean A. Handley、Seung H. Cheon、Vincent A. Parrino

  DOI：10.1021/jm00002a004

  日期：1995.1

  A series of 5-aryl-2,3-dihydroimidazo[2,1-a]isoquinolines previously reported to be platelet activating factor (PAF) receptor antagonists were evaluated for potential antitumor activity. Several compounds, such as the 5-(4'-tert-butylphenyl) (65), 5-[4'-(trimethylsilyl)phenyl] (69), and 5-(4'-cyclohexylphenyl) (71) analogs showed very good cytotoxicity against several tumor cell lines. 5-[4'-(Pipe

  评估了一系列先前报道为血小板活化因子（PAF）受体拮抗剂的5-芳基-2,3-二氢咪唑并[2,1-a]异喹啉的潜在抗肿瘤活性。几种化合物，例如5-（4'-叔丁基苯基）（65），5- [4'-（三甲基甲硅烷基）苯基]（69）和5-（4'-环己基苯基）（71）类似物显示出对几种肿瘤细胞系具有良好的细胞毒性。5- [4'-（哌啶子基甲基）苯基] -2,3-二氢咪唑并[2,1-a]异喹啉（SDZ 62-434，53）在毫克每千克的基础上比临床细胞生长抑制剂edelfosine更有效（1 ）在口服小鼠Meth A纤维肉瘤试验中增加存活率并减少肿瘤体积。它被选作进一步开发，目前正在癌症患者的I期临床试验中。
• Retinoidal Pyrimidinecarboxylic Acids. Unexpected Diaza-Substituent Effects in Retinobenzoic Acids.
  作者：Kiminori OHTA、Emiko KAWACHI、Noriko INOUE、Hiroshi FUKASAWA、Yuichi HASHIMOTO、Akiko ITAI、Hiroyuki KAGECHIKA

  DOI：10.1248/cpb.48.1504

  日期：——

  Several pyridine-and pyrimidine-carboxylic acids were synthesized as ligand candidates for retinoid nuclear receptors, retinoic acid receptors (RARs) and retinoic X receptors (RXRs). Although the pyridine derivatives, 6-[(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthalenyl)carbamoyl]pyridine-3-carboxylic acid (2b) and 6-[(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthalenyl)carboxamido]pyridine-3-carboxylic acid (5b) are more potent than the corresponding benzoic acid-type retinoids, Am80 (2a) and Am580 (5a), the replacement of the benzene ring of Am580 (5a), Am555 (6a), or Am55 (7a) with a pyrimidine ring caused loss of the retinoidal activity both in HL-60 cell differentiation assay and in RAR transactivation assay using COS-1 cells. On the other hand, pyrimidine analogs (PA series, 10 and 11) of potent RXR agonists (retinoid synergists) with a diphenylamine skeleton (DA series, 8 and 9) exhibited potent retinoid synergistic activity in HL-60 cell differentiation assay and activated RXRs. Among the synthesized compounds, 2-[N-n-propyl-N-(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthalenyl)amino]pyrimidene-5-carboxylic acid (PA013, 10e) is most active retinoid synergist in HL-60 assay.

  几种吡啶和嘧啶羧酸被合成为视黄酸核受体、视黄酸受体（RARs）和视黄酸X受体（RXRs）的配体候选物。虽然吡啶衍生物，6-[(5, 6, 7, 8-四氢-5, 5, 8, 8-四甲基-2-萘基)氨基甲酰]吡啶-3-羧酸（2b）和6-[(5, 6, 7, 8-四氢-5, 5, 8, 8-四甲基-2-萘基)羧酰胺]吡啶-3-羧酸（5b）比相应的苯甲酸型视黄酸更有效，如Am80（2a）和Am580（5a），但将Am580（5a）、Am555（6a）或Am55（7a）的苯环替换为嘧啶环会导致视黄酸活性在HL-60细胞分化试验和使用COS-1细胞的RAR转录激活试验中丧失。另一方面，具有二苯胺骨架（DA系列，8和9）的强效RXR激动剂（视黄酸协同剂）的嘧啶类似物（PA系列，10和11）在HL-60细胞分化试验中表现出强效的视黄酸协同活性并激活RXRs。在合成的化合物中，2-[N-正丙基-N-(5, 6, 7, 8-四氢-5, 5, 8, 8-四甲基-2-萘基)氨基]嘧啶-5-羧酸（PA013，10e）在HL-60试验中是最活跃的视黄酸协同剂。
• RETINOID PRODRUG COMPOUND
  申请人：Muratake Hideaki

  公开号：US20100286427A1

  公开（公告）日：2010-11-11

  A compound represented by the following general formula (I): [R 1 to R 5 represent hydrogen atom, an alkyl group, or a trialkylsilyl group, X represents —NH—CO—, —CO—NH—, —N(COR 6 )—CO—, —CO—N(COR 7 )— (R 6 and R 7 represent a lower alkoxy group, or a carboxy-substituted phenyl group) etc.; and Z represents —Y—CH(R 12 )—COOH, —CHO, —CH═CH—COOH, or —COOR 13 (Y represents a single bond, —CH 2 —, —CH(OH)—, —CO—, —CO—NH—, or —CO—NH—CH 2 —CO—NH—, R 12 represents hydrogen atom or a lower alkyl group, and R 13 represents hydrogen atom, —CH(R 14 )—COOH(R 14 represents hydrogen atom, a lower alkyl group, or hydroxy group), —[CH 2 CH 2 —O] n —CH 2 —CH 2 —OH, —CH 2 —O—[CH 2 CH 2 —O] m —CH 2 —OH, or —[CH(CH 3 )—CO—O] p —CH(CH 3 )—COOH (m, n and p represent an integer of 1 to 100))], a salt thereof or an ester thereof, which has a property of being converted into a retinoid after absorption in vivo.

  由以下一般式（I）表示的化合物： [R1至R5代表氢原子、烷基或三烷基硅基，X代表—NH—CO—、—CO—NH—、—N(COR6)—CO—、—CO—N(COR7)—（R6和R7代表较低的烷氧基或羧基取代的苯基）等；Z代表—Y—CH(R12)—COOH、—CHO、—CH═CH—COOH或—COOR13（Y代表单键、—CH2—、—CH(OH)—、—CO—、—CO—NH—或—CO—NH—CH2—CO—NH—，R12代表氢原子或较低的烷基，R13代表氢原子、—CH(R14)—COOH（R14代表氢原子、较低的烷基或羟基），—[CH2CH2—O]n—CH2—CH2—OH、—CH2—O—[CH2CH2—O]m—CH2—OH或—[CH(CH3)—CO—O]p—CH(CH3)—COOH（m、n和p代表1至100的整数）]，其盐或酯，具有在体内吸收后转化为视黄醇类物质的特性。
• THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA
  申请人：Baba Masanori

  公开号：US20110172185A1

  公开（公告）日：2011-07-14

  An object is to provide a novel therapeutic drug for adult T-cell leukemia having an ATL cell specific antitumor effect. The therapeutic drug for adult T-cell leukemia according to the invention is characterized by containing a compound represented by the formula I or a prodrug thereof, wherein R 1 is H, OH, an alkoxy group, an acyl group, or a thioacyl group, R 2 is an acyl group, a thioacyl group, CONR 7 R 8 , or CSNR 7 R 8 (R 7 and R 8 being each independently H, an alkyl group containing 1 to 3 carbon atoms, or a phenyl group), or R 1 and R 2 together may form a ring, X 1 and X 2 may be the same or different and are each —CR 3 R 4 —, —SiR 3 R 4 — or oxygen, and R 3 and R 4 may be the same or different and are each an alkyl group containing 1 to 6 carbon atoms.

  一种提供成人T细胞白血病的新型治疗药物的对象是具有ATL细胞特异性抗肿瘤作用。根据本发明的成人T细胞白血病治疗药物的特征在于含有由式I表示的化合物或其前药， 其中R 1 为H、OH、烷氧基、酰基或硫酰基，R 2 为酰基、硫酰基、CONR 7 R 8 或CSNR 7 R 8 （R 7 和R 8 各自独立地为H、含有1至3个碳原子的烷基或苯基），或R 1 和R 2 可共同形成环，X 1 和X 2 可以相同也可以不同，分别为—CR 3 R 4 —、—SiR 3 R 4 —或氧，R 3 和R 4 可以相同也可以不同，分别为含有1至6个碳原子的烷基。